These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2060971

  • 1. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin.
    Basu S, Sodhi A, Singh SM, Suresh A.
    Immunol Lett; 1991 Mar; 27(3):199-204. PubMed ID: 2060971
    [Abstract] [Full Text] [Related]

  • 2. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565.
    Sodhi A, Basu S.
    Nat Immun; 1992 Mar; 11(2):105-16. PubMed ID: 1498519
    [Abstract] [Full Text] [Related]

  • 3. Interaction between lymphokine activated killer cells generated in the presence of cisplatin/FK-565 and tumor cells: transmission electron microscopy analysis.
    Basu S, Sodhi A.
    Anticancer Drugs; 1992 Apr; 3(2):155-62. PubMed ID: 1525394
    [Abstract] [Full Text] [Related]

  • 4. Up-regulation of IL-2 induced lymphokine activated killer cell activity by cisplatin and FK-565: involvement of calcium ion.
    Sodhi A, Basu S.
    Immunol Lett; 1992 Apr; 32(2):139-46. PubMed ID: 1612637
    [Abstract] [Full Text] [Related]

  • 5. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565.
    Basu S, Sodhi A.
    Immunol Cell Biol; 1992 Feb; 70 ( Pt 1)():15-24. PubMed ID: 1639431
    [Abstract] [Full Text] [Related]

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
    Sone S, Kunishige E, Fawzy F, Yanagawa H, Nii A, Maeda K, Atagi S, Heike Y, Nishioka Y, Mizuno K.
    Jpn J Cancer Res; 1991 Jun 15; 82(6):716-23. PubMed ID: 1649813
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 Jun 15; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 12. The regulation and biological activity of interleukin 12.
    Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS.
    Leuk Lymphoma; 1998 May 15; 29(5-6):427-38. PubMed ID: 9643557
    [Abstract] [Full Text] [Related]

  • 13. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP, Manning LS, Robinson BW.
    Clin Exp Immunol; 1990 Oct 15; 82(1):151-6. PubMed ID: 2208789
    [Abstract] [Full Text] [Related]

  • 14. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
    Atagi S, Sone S, Fukuta K, Ogura T.
    Jpn J Cancer Res; 1992 Oct 15; 83(10):1088-94. PubMed ID: 1452461
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O, Ravindranath Y, Savaşan S.
    J Immunother; 2005 Oct 15; 28(1):44-52. PubMed ID: 15614044
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.
    Klingemann HG, Wong E.
    Cancer Immunol Immunother; 1991 Oct 15; 33(6):395-7. PubMed ID: 1715237
    [Abstract] [Full Text] [Related]

  • 18. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG, Zeuthen J, Claësson MH.
    Nat Immun; 1992 Oct 15; 11(1):7-16. PubMed ID: 1611282
    [Abstract] [Full Text] [Related]

  • 19. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA, Wright C, Forman SJ.
    Leukemia; 1997 May 15; 11(5):723-8. PubMed ID: 9180298
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.